BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is projected to release its earnings data before the market opens on Monday, March 31st. Analysts expect BioHarvest Sciences to post earnings of ($0.12) per share and revenue of $7.24 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
BioHarvest Sciences Price Performance
BHST stock remained flat at $6.71 during trading hours on Tuesday. The company had a trading volume of 5,515 shares, compared to its average volume of 8,297. The stock has a 50 day moving average of $5.60. The firm has a market cap of $110.21 million, a price-to-earnings ratio of -5.37 and a beta of 2.27. BioHarvest Sciences has a fifty-two week low of $6.71 and a fifty-two week high of $7.38.
Analyst Ratings Changes
BHST has been the subject of several research reports. HC Wainwright started coverage on shares of BioHarvest Sciences in a research report on Friday, December 6th. They set a "buy" rating and a $14.00 price objective for the company. Maxim Group assumed coverage on shares of BioHarvest Sciences in a report on Wednesday, December 18th. They set a "buy" rating and a $12.00 target price for the company.
View Our Latest Stock Analysis on BHST
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Read More
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
